ClinicalTrials.gg
RecruitingNCT06798740T2_PMCFUpdated Feb 9, 2026

Post Market Registry Study of Intracranial Aneurysms Treated With Sugita Clipping Devices

An observational study in Brain Aneurysm, sponsored by Mizuho Corporation. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Mizuho Corporation · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Intracranial Aneurysm with a site in Germany — 9 open to participants now, 14 under way, none of them phase 3. Intracranial Aneurysm · Germany.

Planned enrollment
22nd of 32
150 · median 206
Started
2025
the only one that year
Observational
33 of 46
8 open now
Primary completion
2027-02
later than 6 of 13 live
Registered
44th of 46
by date

Among the 46 studies in Intracranial Aneurysm with a site in Germany, this one is the 22nd largest by planned enrollment of the 32 observational ones that give a count, is the only one that started in 2025, is one of 33 observational ones, reaches primary completion later than 6 of the 13 other live ones, and was the 44th registered.

Intracranial Aneurysm

419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

Browse Intracranial Aneurysm studies →

Open to participants now

9 of the 46 studies in Intracranial Aneurysm with a site in Germany are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Intracranial Aneurysm with a site in Germany, or all of them as a file.
02

Study summary

The objective of this study is to verify the performance and safety of the Sugita Aneurysm Clips devices when used as intended and to identify possible risk factors. Data collected will be used to support the continuing performance and safety of the devices in the post-market use environment in Europe. Subjects who have an intracranial aneurysm that the physician intends to treat with the subject devices will be included in the study. Subjects will be followup as per hospital standard of care for 5 years.

03

Conditions studied

  • Brain Aneurysm

Browse trials for

Keywords

  • clip
  • sugita
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects who have an intracranial aneurysm (ruptured or unruptured) that the physician intends to treat with the subject device(s)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has an intracranial aneurysm (ruptured or unruptured) that can be treated with one of the proposed devices.
  • Subject is adult, ≥18 years.
  • As per national regulations, subject or subject's legally authorized representative (LAR) has signed written .
  • Subject is willing to comply with scheduled visits and examinations per institutional standard of care.

Exclusion criteria

Exclusion Criteria:

  • Subject is currently enrolled in or plans to be enrolled in a concurrent drug or device randomized study.
  • Subject has a condition which will not allow him/her to comply with his/her post-procedure follow up per the institutional standard of care (medical condition, subject living abroad and unable to return for follow- up, e.g.).
  • Subject does not meet IFU criteria of the subject device.
  • Subject is a child, \<18 years.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Aneurysm clip

    Patients presenting intracranial aneurysm (ruptured or unruptured) that the physician intends to treat with the Sugita clips.

    Device: Sugita Titanium Aneurysm Clip II

Interventions

  • DeviceSugita Titanium Aneurysm Clip II

    Aneurysm clipping is a surgical procedure used to treat brain aneurysms.

06

What researchers measure

Primary outcomes

  1. Rate of permanent aneurysm occlusions

    Rate of complete permanent aneurysm occlusions according to Molyneux et al, 2005, where the category of occlusion is selected as "Complete occlusion".

    Time frame: Up to 12 months

Secondary outcomes

  1. Incidence of adverse events

    The number and percentage of subjects experiencing any adverse event. Each adverse event type, including severity will be reported.

    Time frame: up to 60 months

  2. Change in Modified Rankin Scale

    The mean, standard deviation, median, minimum, maximum, and number of evaluable observations will be reported for baseline and to each follow up visit using descriptive statistics.The absolute change from baseline will be calculated for each subject at follow up visits.

    Time frame: through 60 months

  3. Amount of aneurysm retreatments

    The amount of aneurysm retreatments will be reported as 0, 1 and \>=2 retreatments through each follow up visit.

    Time frame: through 60 months

  4. Procedure success rate

    Rate of successful aneurysm occlusions per Molyneux classification "Complete occlusion" while using a permanent clip. Frequency counts and percentages of subjects, as well as 95% confidence intervals for the percentages will be presented.

    Time frame: within 1 week after clipping

  5. Rate of successful applications of temporary clips

    Subjects that experience a successful aneurysm occlusion according to Molyneux classification "Complete occlusion" while using temporary clips.

    Time frame: Within 1 week after clipping

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Feb 2027, 22 months after the start.

Of 68 non-industry observational studies under Intracranial Aneurysm, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 145. This study's planned 22 months is below that.

Counting every sponsor, half of 105 studies reached it within 46 months; a quarter within 36 and three quarters within 145.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2025
First posted
Jan 29, 2025
StartActual
Apr 14, 2025
Primary completionEst.
Feb 14, 2027
CompletionEst.
Feb 14, 2033
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06798740
Lead sponsor
Mizuho Corporation
Responsible party
Sponsor
First posted
Jan 29, 2025
Start date
Apr 14, 2025
Primary completion
Feb 14, 2027 (estimated)
Completion
Feb 14, 2033 (estimated)
Last update
Feb 9, 2026

Study contacts

Mai Hamayoshi
Contact
m.hamayoshi@mizuho.co.jp
+81-3-3815-3180

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion